Debra Patt and Tara Graff open this Insights series by examining why CAR T-cell therapy access remains geographically concentrated, drawing parallels to earlier waves of specialized cancer treatment adoption.
Accreditation, Access, and Outcomes: What Real-World CAR-T Data Tells Us
Dr. Graff details how rural geography and unfavorable payer reimbursement compound to limit which community oncology practices can safely and sustainably offer T-cell engaging therapies.
Advertisement
Advertisement
Trending on AJMC
1
GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH
2
$20 Billion National Strategy Aims to Close the Women's Health Gap
3
Smartwatch Study Links Midlife to Rising Nighttime Awakenings in Women
4
5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care
5